These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 9752713)

  • 21. Justification for the use of aseptic filling for sterile injectable products.
    Cundell AM
    PDA J Pharm Sci Technol; 2014; 68(4):323-32. PubMed ID: 25035255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Bayesian Approach to Determination of
    Faya P; Stamey JD; Seaman JW
    PDA J Pharm Sci Technol; 2017; 71(2):88-98. PubMed ID: 27789802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of conditions for the production scale sterilization of prefilled syringes.
    Nishimoto N; Maekawa T
    PDA J Pharm Sci Technol; 2003; 57(5):378-86. PubMed ID: 14677630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Product Sterility Testing . . . To Test or Not to Test? That Is the Question.
    Daniell E; Bryans T; Darnell K; Hansen J; Hitchins VM; Saavedra M
    Biomed Instrum Technol; 2016 Apr; 50 Suppl 3():35-43. PubMed ID: 27100074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achieving "Zero" Defects for Visible Particles in Injectables.
    Johns J; Golfetto P; Bush T; Fantozzi G; Shabushnig J; Perry A; Degrazio F; Streich D; Miller J; Soukiassian H; Stanton A; Watson R
    PDA J Pharm Sci Technol; 2018; 72(6):640-650. PubMed ID: 30232141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancing Patient Safety through the Use of a Pharmaceutical Glass Designed To Prevent Cracked Containers.
    Schaut RA; Hoff KC; Demartino SE; Denson WK; Verkleeren RL
    PDA J Pharm Sci Technol; 2017; 71(6):511-528. PubMed ID: 28928290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Preliminary study on suitability of ozone sterilization in traditional Chinese medicine and its preparation].
    Hu YJ; Wang YQ; Wu ZF; Lan JP; Zhang LG; Yang M
    Zhongguo Zhong Yao Za Zhi; 2015 Aug; 40(16):3137-41. PubMed ID: 26790281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in the Manual Visual Inspection of the Interior Surfaces of Single-Use Systems for the Presence of Particulate Matter.
    Wormuth K; Benoit O; Kateb D; Laruelle D
    PDA J Pharm Sci Technol; 2021; 75(4):332-340. PubMed ID: 33608472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new coincidence model for single particle counters, part III: realization of single particle counting accuracy.
    Knapp JZ; Abramson LR
    PDA J Pharm Sci Technol; 1996; 50(2):99-122. PubMed ID: 8935778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sterility testing of cell therapy products: parallel comparison of automated methods with a CFR-compliant method.
    Khuu HM; Patel N; Carter CS; Murray PR; Read EJ
    Transfusion; 2006 Dec; 46(12):2071-82. PubMed ID: 17176318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parametric Release of Moist Heat Sterilized Products: History and Current State.
    Sadowski MJ; Langille SE
    PDA J Pharm Sci Technol; 2022; 76(6):527-536. PubMed ID: 35840343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new coincidence model for single particle counters, Part I: Theory and experimental verification.
    Knapp JZ; Abramson LR
    J Pharm Sci Technol; 1994; 48(3):110-34. PubMed ID: 8069513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Particulate Generation Mechanisms during Bulk Filling and Mitigation via New Glass Vial.
    Timmons CL; Liu CY; Merkle S
    PDA J Pharm Sci Technol; 2017; 71(5):379-392. PubMed ID: 28512178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adventitious contamination of intravenous admixtures during sterility testing.
    Bernick JJ; Brown DG; Bell JE
    Am J Hosp Pharm; 1979 Nov; 36(11):1493-6. PubMed ID: 517534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential application of quantitative microbiological risk assessment techniques to an aseptic-UHT process in the food industry.
    Pujol L; Albert I; Johnson NB; Membré JM
    Int J Food Microbiol; 2013 Apr; 162(3):283-96. PubMed ID: 23454820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why and how to implement a rapid sterility test.
    Gressett G; Vanhaecke E; Moldenhauer J
    PDA J Pharm Sci Technol; 2008; 62(6):429-44. PubMed ID: 19634346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation study on how to avoid microbial contamination during pharmaceutical production.
    Shintani H
    Biocontrol Sci; 2015; 20(1):1-10. PubMed ID: 25817807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.